Extended Data Fig. 2: Respiratory viral infections induce pulmonary anti-tumor immunity.
(a) Quantification of B16 tumor burdens in PBS or IAV-infected mice. (b) Representative Masson’s trichrome staining images of B16 tumor-bearing lungs from PBS or IAV-infected mice. Quantification of B16 cells based on RT-PCR (c) or flow cytometry (d) analysis in the lungs of PBS or IAV mice early post i.v. inoculation of B16-luc expressing GFP. (e) Macroscopy of lungs and (f) number of B16 tumor nodules on the lung surface in PBS and day 60 IAV-infected (IAVd60) mice. (g) Representative lung histopathology images and (h) percentage of lung area occupied by tumor lesions in mice shown in (e). (i) Macroscopy of lungs and (j) number of B16 tumor nodules on the lung surface in PBS and day 30 IAV- or AdV-infected mice. (k) Representative lung histopathology and (l) percentage of lung area occupied by tumor lesions in mice shown in (i). (m) Schema of subcutaneous (s.c.) B16 tumor model. (n) Kinetic changes in subcutaneous B16 tumor size at the injection site. (o) Macroscopy and (p) weight of subcutaneous B16 tumors at endpoint. (q) Kinetics of subcutaneous tumor volume after inoculation of 4T1 cells in PBS or IAV-infected mice (*p = 0.0336). (r) Schema of bone marrow transplantation (BMT). (s) Percentage of donor-derived peripheral blood myeloid cells at 35 days post BMT. (t) average radiance of luciferin signals in the lung area and (u) number of B16 tumor nodules on the lung surface in mice shown in (r). Bar graphs are presented as mean ± SD. Data are representatives of two independent experiments (n = 3 mice per group in a,c,d; n = 5 mice per group in b,f,h; n = 6 mice in PBS and IAV groups and n = 4 mice in AdV group in j,l; n = 4 mice per group in n,p,q; n = 6 mice per group in s,t,u). Two-tailed Student t test was performed for comparisons between two groups. One-way ANOVA followed by a Tukey test was performed to compare more than two groups.
